Apogee Therapeutics (APGE) CEO sells 20,000 shares in planned trades, keeps over 1.09M

Filing Impact

(Very High)

Filing Sentiment

(Negative)

Form Type

Rhea-AI Filing Summary

Apogee Therapeutics, Inc. Chief Executive Officer Michael Thomas Henderson reported multiple open-market sales of common stock. On June 10, 2026, he sold a total of 20,000 shares of Apogee common stock in several transactions under a previously adopted Rule 10b5-1 trading plan dated August 13, 2025. Reported sale prices for these trades include individual weighted-average prices such as $82.78 and $86.89 per share, with underlying trade ranges detailed in the footnotes. Following these sales, Henderson continued to directly own 1,095,987 shares of Apogee common stock.

Insider Trade Summary 10b5-1

Net Seller: 20,000 shares ($1,667,622)

Net Sell 6 txns

Insider HENDERSON MICHAEL THOMAS

Role Chief Executive Officer

Sold 20,000 shs ($1.67M)

Type	Security	Shares	Price	Value
Sale	Common Stock	6,770	$82.21	$557K
Sale	Common Stock	7,654	$82.78	$634K
Sale	Common Stock	1,080	$84.18	$91K
Sale	Common Stock	1,577	$85.19	$134K
Sale	Common Stock	2,305	$86.27	$199K
Sale	Common Stock	614	$86.89	$53K

Holdings After Transaction: Common Stock — 1,109,217 shares (Direct, null)

Footnotes (1)

This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on August 13, 2025. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $81.57 to $82.56, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $82.57 to $83.33, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $83.595 to $84.50, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $84.71 to $85.665, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $85.74 to $86.70, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $86.835 to $87.165, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.

Key Figures

Shares sold: 20,000 shares Post-transaction holdings: 1,095,987 shares Sale price example: $82.78 per share +3 more

6 metrics

Shares sold 20,000 shares Total common stock sold on June 10, 2026

Post-transaction holdings 1,095,987 shares CEO’s direct common stock ownership after sales

Sale price example $82.78 per share Weighted-average price for one transaction block

Sale price example $86.89 per share Weighted-average price for another transaction block

Sale transactions 6 transactions Open-market sales coded as S on June 10, 2026

Trading plan date August 13, 2025 Adoption date of Rule 10b5-1 trading plan

Key Terms

Rule 10b5-1 trading plan, weighted average price, open-market sale, Form 4

4 terms

Rule 10b5-1 trading plan regulatory

"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on August 13, 2025."

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

weighted average price financial

"The price reported above is a weighted average price. The shares were sold in multiple transactions..."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

open-market sale financial

"transaction_action: "open-market sale", transaction_code_description: "Sale in open market or private transaction""

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

Form 4 regulatory

"INSIDER FILING DATA (Form 4): { "issuerName": "Apogee Therapeutics, Inc.""

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

06/12/2026 - 05:05 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

HENDERSON MICHAEL THOMAS

(Last)

(First)

(Middle)

C/O APOGEE THERAPEUTICS, INC.

221 CRESCENT ST., BLDG. 17, STE. 102B

(Street)

WALTHAM

MASSACHUSETTS

02453

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Apogee Therapeutics, Inc. [ APGE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Executive Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/10/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	06/10/2026		S⁽¹⁾		6,770	D	$82.21⁽²⁾	1,109,217	D
Common Stock	06/10/2026		S⁽¹⁾		7,654	D	$82.78⁽³⁾	1,101,563	D
Common Stock	06/10/2026		S⁽¹⁾		1,080	D	$84.18⁽⁴⁾	1,100,483	D
Common Stock	06/10/2026		S⁽¹⁾		1,577	D	$85.19⁽⁵⁾	1,098,906	D
Common Stock	06/10/2026		S⁽¹⁾		2,305	D	$86.27⁽⁶⁾	1,096,601	D
Common Stock	06/10/2026		S⁽¹⁾		614	D	$86.89⁽⁷⁾	1,095,987	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on August 13, 2025.

2. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $81.57 to $82.56, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range.

3. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $82.57 to $83.33, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.

4. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $83.595 to $84.50, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.

5. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $84.71 to $85.665, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.

6. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $85.74 to $86.70, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.

7. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $86.835 to $87.165, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.

	/s/ Matthew Batters, as attorney-in-fact for Michael Henderson	06/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did Apogee Therapeutics (APGE) report for its CEO?

Apogee Therapeutics reported that CEO Michael Thomas Henderson sold 20,000 shares of common stock in open-market transactions. These trades occurred on June 10, 2026 and were executed in multiple blocks at different prices, all disclosed in the Form 4 footnotes.

How many Apogee Therapeutics (APGE) shares does the CEO hold after the sale?

After the reported transactions, CEO Michael Thomas Henderson directly holds 1,095,987 shares of Apogee common stock. This post-transaction holding is disclosed in the Form 4 and reflects his remaining ownership following the 20,000 shares sold on June 10, 2026.

Were the Apogee Therapeutics (APGE) CEO’s stock sales made under a Rule 10b5-1 plan?

Yes. The filing states the CEO’s June 10, 2026 stock sales were executed under a Rule 10b5-1 trading plan adopted on August 13, 2025. Such plans pre-schedule trades, helping separate routine liquidity management from discretionary market-timed decisions.

At what prices did the Apogee Therapeutics (APGE) CEO sell shares?

The Form 4 reports weighted-average sale prices including $82.78, $82.21, $84.18, $85.19, $86.27 and $86.89 per share. Footnotes explain these are averages over many individual trades, with detailed price ranges available upon request from the issuer or the SEC.

How many separate stock sale transactions did the Apogee Therapeutics (APGE) CEO execute?

The filing lists six separate open-market sale transactions on June 10, 2026. Together, these sales total 20,000 shares of Apogee common stock, with each line item showing its own weighted-average sale price and the CEO’s direct share balance following that transaction.

Does the Apogee Therapeutics (APGE) Form 4 show any option exercises or gifts?

No. The summarized Form 4 data show only open-market sales of common stock coded as “S.” There are no reported option exercises, tax-withholding dispositions, gifts, or derivative security transactions in this particular filing’s transaction summary.